Boston Scientific (NYSE:BSX) Price Target Raised to $64.00 at Canaccord Genuity Group

Boston Scientific (NYSE:BSX – Free Report) had its price target raised by Canaccord Genuity Group from $60.00 to $64.00 in a report released on Monday, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the medical equipment provider’s stock. A number of other equities research analysts have also weighed in on BSX. Mizuho […]

Leave a Reply

Your email address will not be published.

Previous post Lifezone Metals (NYSE:LZM) Given “Buy” Rating at Roth Capital
Next post HC Wainwright Reaffirms “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT)